RhoGDI Antibody [H2N24]

Catalog No.: F3955

Application: Reactivity: Mouse, Human

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 - 1:10000 IHC1:100 - 1:250

Application
WB, IHC

Source
Rabbit Monoclonal Antibody

Reactivity
Mouse, Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
23 kDa 27 kDa, 23 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
RhoGDI Antibody [H2N24] detects endogenous levels of total RhoGDI protein.

Clone
H2N24

Synonym(s)
GDIA1; ARHGDIA; Rho GDP-dissociation inhibitor 1; Rho GDI 1; Rho-GDI alpha

Background
RhoGDI (Rho GDP-dissociation inhibitor 1, RhoGDIα/ARHGDIA) is a regulatory protein of the RhoGDI family that governs the cycling of Rho GTPases (such as RhoA, Rac1, and Cdc42) between their inactive, cytosolic GDP-bound and active, membrane-associated GTP-bound states. RhoGDI features a flexible N-terminal regulatory domain (residues 1–69) that adopts a helix-loop-helix motif (residues 34–57) upon GTPase binding to occlude switch I/II regions, and a C-terminal immunoglobulin-like β-sandwich domain (residues 70–204) with a conserved hydrophobic pocket (lined by Ile177, Val184) for binding the geranylgeranyl lipid anchor; Arg66 bridges the two domains, stabilizing the inhibitory conformation. RhoGDI controls Rho GTPase activity by sterically blocking GEF access (inhibiting GDP dissociation), extracting prenylated GDP-bound GTPases from membranes through lipid sequestration, and shuttling them in the cytosol or delivering them to specific membrane sites for spatiotemporal activation. Through this regulation, RhoGDI orchestrates actin cytoskeleton dynamics, lamellipodia and ruffle formation, cell migration, polarity, and adhesion, integrating into Rho/ROCK/mDia1 and Rac/PAK/WAVE signaling pathways responsive to growth factors and integrins. Dysregulation of RhoGDI is implicated in cancer metastasis via hyperactive Rho signaling in breast and prostate cancers and neurodegeneration, such as Alzheimer’s disease, through disrupted neuronal morphogenesis.

Background

RhoGDI (Rho GDP-dissociation inhibitor 1, RhoGDIα/ARHGDIA) is a regulatory protein of the RhoGDI family that governs the cycling of Rho GTPases (such as RhoA, Rac1, and Cdc42) between their inactive, cytosolic GDP-bound and active, membrane-associated GTP-bound states. RhoGDI features a flexible N-terminal regulatory domain (residues 1–69) that adopts a helix-loop-helix motif (residues 34–57) upon GTPase binding to occlude switch I/II regions, and a C-terminal immunoglobulin-like β-sandwich domain (residues 70–204) with a conserved hydrophobic pocket (lined by Ile177, Val184) for binding the geranylgeranyl lipid anchor; Arg66 bridges the two domains, stabilizing the inhibitory conformation. RhoGDI controls Rho GTPase activity by sterically blocking GEF access (inhibiting GDP dissociation), extracting prenylated GDP-bound GTPases from membranes through lipid sequestration, and shuttling them in the cytosol or delivering them to specific membrane sites for spatiotemporal activation. Through this regulation, RhoGDI orchestrates actin cytoskeleton dynamics, lamellipodia and ruffle formation, cell migration, polarity, and adhesion, integrating into Rho/ROCK/mDia1 and Rac/PAK/WAVE signaling pathways responsive to growth factors and integrins. Dysregulation of RhoGDI is implicated in cancer metastasis via hyperactive Rho signaling in breast and prostate cancers and neurodegeneration, such as Alzheimer’s disease, through disrupted neuronal morphogenesis.

References
[1] Dovas A, et al. Biochem J. 2005 Aug 15;390(Pt 1):1-9. [2] Dransart E, et al. Traffic. 2005 Nov;6(11):957-66.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%